Delivery Order SPE2DU25D9421-SPE2DU26FELPY

The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $29,187.13 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on November 7, 2025, with an ultimate completion date of November 10, 2025, was executed without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying pharmaceutical products to Department of Defense healthcare facilities worldwide.

Under the PPV-G GEN V program, DMS Pharmaceutical Group is authorized to supply a comprehensive range of pharmaceutical products including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables to support recurring medical supply needs across military healthcare operations globally. The company's product portfolio encompasses critical therapeutic categories ranging from oncology treatments and immunosuppressants to emergency medications, surgical products, and routine pharmaceuticals. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 with an ultimate completion date of December 31, 2036, structured as a 30-month base period with three 30-month option periods, positioning DMS Pharmaceutical Group as a strategic pharmaceutical supplier for Department of Defense healthcare operations.